# Valenta Pharm JSC clinical trials: 40 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 40 trials with Valenta Pharm JSC as lead sponsor, 12 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Valenta Pharm JSC: 40 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/valenta-pharm-jsc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 40
- Recruiting or not yet: 12
- Read on: November 19, 2026

## Trials

The 25 newest of 40, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 12, 2026 | NCT07645534 | Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90... | Valenta Pharm JSC | Phase 1 | Recruiting | Influenza, Acute Respiratory Viral Infections | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645534) |
| May 19, 2026 | NCT07595003 | Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia | Valenta Pharm JSC | Phase 3 | Recruiting | Chronic Cholecystitis, Biliary Dyskinesia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595003) |
| May 19, 2026 | NCT07594977 | Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy Volunteers | Valenta Pharm JSC | Phase 1 | Recruiting | Chronic Cholecystitis, Biliary Dyskinesia | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594977) |
| February 19, 2026 | NCT07421011 | Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in... | Valenta Pharm JSC | Phase 1 | Recruiting | Irritable Bowel Syndrome, Gallstone Disease, GERD, Biliary Dyskinesia, Postcholecystectomy Syndrome | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421011) |
| February 19, 2026 | NCT07420985 | Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects... | Valenta Pharm JSC | Phase 2 | Recruiting | Influenza, Acute Respiratory Viral Infection | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07420985) |
| March 5, 2025 | NCT06859333 | Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and... | Valenta Pharm JSC | Phase 1 | Recruiting | Influenza, Viral Respiratory Infection | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859333) |
| March 5, 2025 | NCT06859281 | Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers | Valenta Pharm JSC | Phase 1 | Recruiting | Pharyngitis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859281) |
| March 5, 2025 | NCT06857890 | Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers | Valenta Pharm JSC | Phase 1 | Recruiting | Pharyngitis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06857890) |
| February 24, 2025 | NCT06843044 | Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders | Valenta Pharm JSC | Phase 4 | Recruiting | Anxiety, Neurasthenia, Adjustment Disorders | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06843044) |
| February 24, 2025 | NCT06843018 | Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment... | Valenta Pharm JSC | Phase 2 | Recruiting | Pharyngitis Acute, Pharyngitis, Nasopharyngitis, Exacerbation of Chronic Pharyngitis | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06843018) |
| February 24, 2025 | NCT06842966 | Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia | Valenta Pharm JSC | Phase 2 | Recruiting | Chronic Cholecystitis, Biliary Dyskinesia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06842966) |
| August 14, 2024 | NCT06552624 | Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in... | Valenta Pharm JSC | Not applicable | Completed | Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract, Symptomatic Treatment of Gastric and Duodenal Ulcers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06552624) |
| April 23, 2024 | NCT06379542 | Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections | Valenta Pharm JSC | Phase 3 | Unknown | Acute Respiratory Infection | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06379542) |
| April 2, 2024 | NCT06342804 | Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg | Valenta Pharm JSC | Phase 1 | Unknown | Cholecystitis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06342804) |
| April 2, 2024 | NCT06342778 | Pharmacokinetics and Bioequivalence of Doxylamine+Pyridoxine and Diclectin Under Fed Conditions in Healthy Volunteers | Valenta Pharm JSC | Phase 1 | Completed | Nausea | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06342778) |
| March 20, 2024 | NCT06321341 | Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional... | Valenta Pharm JSC | Phase 4 | Recruiting | Vertigo, Autonomic Dysfunction | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06321341) |
| March 18, 2024 | NCT06315400 | Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections | Valenta Pharm JSC | Phase 4 | Unknown | Influenza, Human, Acute Respiratory Infection, Common Cold | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06315400) |
| March 18, 2024 | NCT06315387 | Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in... | Valenta Pharm JSC | Phase 1 | Unknown | Cholecystitis | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06315387) |
| October 24, 2023 | NCT06098742 | Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets... | Valenta Pharm JSC | Not applicable | Unknown | Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract, Symptomatic Treatment of Gastric and Duodenal Ulcers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06098742) |
| October 24, 2023 | NCT06096571 | Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers | Valenta Pharm JSC | Not applicable | Unknown | Viral Infection COVID-19 | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06096571) |
| October 19, 2022 | NCT05586789 | A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders | Valenta Pharm JSC | Phase 3 | Completed | Anxiety, Neurasthenia, Adjustment Disorders | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05586789) |
| September 30, 2022 | NCT05561816 | Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma | Valenta Pharm JSC | Phase 3 | Completed | Pyoderma | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05561816) |
| September 28, 2022 | NCT05558462 | Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers | Valenta Pharm JSC | Not applicable | Completed | Influenza, Respiratory Viral Infection | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05558462) |
| September 19, 2022 | NCT05544916 | A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory... | Valenta Pharm JSC | Phase 3 | Completed | Influenza, Respiratory Viral Infection | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05544916) |
| August 17, 2022 | NCT05505097 | Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External... | Valenta Pharm JSC | Phase 1 | Completed | Infections | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05505097) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 2 | 5 |
| Phase 3 | 13 |
| Phase 4 | 4 |
| Not applicable | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 22 |
| Recruiting | 12 |
| Unknown | 6 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Influenza, Human | 15 |
| Common Cold | 9 |
| Virus Diseases | 4 |
| Biliary Dyskinesia | 4 |
| Pharyngitis | 3 |
| COVID-19 | 2 |
| Heartburn | 2 |
| Duodenal Ulcer | 2 |
| Anxiety Disorders | 2 |
| Neurasthenia | 2 |
| Adjustment Disorders | 2 |
| Vertigo | 2 |
| Primary Dysautonomias | 2 |
| Nausea | 2 |
| Cholecystitis | 2 |
| Pyoderma | 1 |
| Nasopharyngitis | 1 |
| Irritable Bowel Syndrome | 1 |
| Cholelithiasis | 1 |
| Gastroesophageal Reflux | 1 |
| Postcholecystectomy Syndrome | 1 |
| Infections | 1 |
| Respiratory Tract Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Iron fabricators in the United States](https://specstream.ai/data/businesses/iron-fabricators/united-states)
- [B2B scientific equipment companies in the United States](https://specstream.ai/data/businesses/b2b-scientific-equipment-companies/united-states)
- [Pakistani restaurants in the United States](https://specstream.ai/data/businesses/pakistani-restaurants/united-states)
- [Countertop installers in the United States](https://specstream.ai/data/businesses/countertop-installers/united-states)
- [Shipping collection companies in the United States](https://specstream.ai/data/businesses/shipping-collection-companies/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
